Paediatric Dermatology

Jul 24, 2024 | academic.oup.com | Alcalá de Henares |Paediatric Dermatology

The main conventional systemic atopic dermatitis (AD) treatments are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are no head-to-head randomised controlled trials or real-world studies comparing these agents directly. Network meta-analyses provide indirect comparative efficacy and safety data and have shown strong evidence for dupilumab and CyA.

Sep 19, 2023 | academic.oup.com | Paediatric Dermatology

Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust RCT evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower resource settings. The TREAT trial compared the safety and efficacy of ciclosporin (CyA) versus methotrexate (MTX) in CYP with severe AD.